News and Trends 29 Jul 2024
Influenza solution deals pile up as pandemic preparedness increases
Influenza deals have been piling up in the last few weeks. Discover why that is and how are companies and government preparing for pandemics.
influenza
- Latest Posts
In Depth 11 Jul 2023
AIS Biotech: startup employs carbohydrates to fight the flu
Keen on discovering novel ways to tackle viral infections, AIS Biotech, a French company based in the Alps, aims to combat influenza, more commonly known as the flu, by leveraging the medicinal promise behind glycobiotechnology. A field that has been gaining momentum over the past decade, glycobiotechnology is the study of complex carbohydrates which has […]
News and Trends 29 Jun 2023
AI program finds multiple influenza drug targets
Poolbeg Pharma, a clinical-stage biopharma company focusing on infectious and other prevalent diseases, has announced a breakthrough in its world-first influenza Artificial Intelligence (AI) Programme working with the company CytoReason. Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analyzed using CytoReason’s AI-led platform. The […]
News and Trends 26 Apr 2023
aVaxziPen’s needle-free vaccine yields positive data across multiple diseases
aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, presented data at the World Vaccine Congress (WVC) in Washington, U.S., recently. The company presented a poster entitled, “Needle-free, injectable solid dose vaccine delivery generates equivalent immune response with different antigens and animal models.” The company said immunogenicity data from four in vivo models […]
News and Trends 7 Feb 2023
AAHI bags $9.9M to develop nasal spray influenza RNA vaccine
The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) […]
News and Trends 17 Jan 2023
Poolbeg expands POLB 001 into oncology
Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is a strain agnostic, small molecule immunomodulator being studied to address the unmet medical need for a treatment for severe influenza. While investigating the role of cytokine release syndrome (CRS) in severe influenza, Poolbeg discovered data specific to the overt immune […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 13 Dec 2022
Poolbeg influenza trial successfully completed
Poolbeg Pharma has received initial results having completed its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. The study showed no further clinical activity is required to complete the objectives of the trial, bringing the recruitment […]
Startup Scout 21 Nov 2022
Osivax is designing future-proof influenza and Covid vaccines
Viruses causing influenza and COVID-19 continually evolve to escape our vaccine protections. The French firm Osivax is developing vaccines that are harder for the viruses to evade. Many life-saving vaccines have been developed and approved to protect against viral infections including COVID-19 and influenza. Commercially available vaccines typically activate the production of antibodies against fragments […]
News and Trends 3 Nov 2022
Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits
Rapid test kits that can accurately identify infections related to respiratory syncytial virus (RSV), influenza and Covid-19 can deliver results in 15 minutes. UK-based Virax Biolabs, a biotech company focused on the prevention, detection and diagnosis of viral diseases announced today (November 3) the distribution of a tripe virus antigen rapid test kit has been […]
News and Trends 4 Oct 2022
Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments
Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections. POLB 001 The USPTO granted a patent for the majority of Poolbeg’s claims around the […]
News and Trends 16 Aug 2022
Pneumagen embarks on phase 2 proof of concept influenza study
Biotech company Pneumagen says the first person has been dosed in its phase 2 controlled human infection challenge study. Its product, Neumifil, is an intranasal, broad-spectrum antiviral treatment to prevent or, if infected, reduce and manage, viral respiratory tract infections. The phase 2 trial is a single center, randomized, double-blinded, placebo-controlled study evaluating two dose […]
News and Trends 15 Aug 2022
Roche announces influenza drug approval and new COVID test
Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks […]
ADVERTISEMENT
